No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
DRRX Durect
- 0.8712
- -0.0388-4.26%
Close Apr 19 16:00 ET
- 0.8551
- -0.0161-1.85%
Post 17:57 ET
27.04MMarket Cap-726P/E (TTM)
0.9375High0.8500Low114.57KVolume0.9098Open0.9100Pre Close102.52KTurnover0.39%Turnover RatioLossP/E (Static)31.04MShares7.460052wk High1.83P/B25.84MFloat Cap0.470352wk Low--Dividend TTM29.66MShs Float185.0000Historical High--Div YieldTTM9.62%Amplitude0.4703Historical Low0.8940Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Oppenheimer Reiterates Outperform on Durect, Maintains $5 Price Target
Express News | HC Wainwright & Co. Reiterates Neutral on Durect
Durect Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/28/2024 — HC Wainwright & Co. Reiterates → Neutral 11/09/2023 — JonesTrading Downgrades Buy → Hold 11
H.C. Wainwright Keeps Their Hold Rating on Durect (DRRX)
Q4 2023 DURECT Corp Earnings Call
Earnings Call Summary | Durect(DRRX.US) Q4 2023 Earnings Conference
The following is a summary of the DURECT Corporation (DRRX) Q4 2023 Earnings Call Transcript:Financial Performance:DURECT reported total revenues of $8.5 million in 2023, significantly lower than the
Comments
Novel Therapeutics Company Forms Strategic Collaboration Agreement
DURECT Corporation and Charles River Laboratories: A Strategic Alliance Set to Revolutionize the Biopharmaceutical Industry.
In a significant move within the biopharmaceutical industry, DURECT Corporation (DRRX) has entered into a co-marketing and collaboration agreement with Charles River Laboratories International, Inc. This alliance, announced on March 4, 2024, is set to jointly market and commercialize the ALZET Osmotic Pumps ...
In a significant move within the biopharmaceutical industry, DURECT Corporation (DRRX) has entered into a co-marketing and collaboration agreement with Charles River Laboratories International, Inc. This alliance, announced on March 4, 2024, is set to jointly market and commercialize the ALZET Osmotic Pumps ...
Update
$Durect(DRRX.US$ Durect Corporation Has Entered Into A Co-marketing And Collaboration Agreement With Charles River Laboratories For The Alzet Osmotic Pumps Portfolio And Associated Product Line In The US And Canada
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg